HWH340 / WuXi AppTec, Humanwell Healthcare - LARVOL DELTA

A phase I study evaluating the novel poly ADP-ribose polymerase inhibitor (PARPi)HWH340 in patients with advanced solid tumors, with focus on patients harboring mutations in genes related to homologous recombination repair (HRR) (ESMO 2025) - P1 | "The RP2D was determined to be 200 mg twice daily. The registration number of the ongoing phase II clinical study is CTR20223238."

Clinical • Metastases • P1 data • Breast Cancer • Oncology • Solid Tumor • HRD

Humanwell Pharmaceuticals' Class 1 new drug HWH340 tablets combination therapy approved for clinical use [Google translation] (bydrug.pharmcube.com) - "Recently, Hubei Biomedicine Industry Technology Research Institute Co., Ltd...received the 'Drug Clinical Trial Approval Notice' for HWH340 tablets issued by the National Medical Products Administration, approving the product to conduct clinical trials for the indication of combined use with abiraterone acetate for advanced prostate cancer."

New trial • Prostate Cancer

Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=85; Recruiting; Sponsor: Hubei Biological Medicine Industrial Technology Institute Co., Ltd.; N=45 ➔ 85; Trial completion date: Jun 2019 ➔ Sep 2021; Trial primary completion date: Jun 2019 ➔ Mar 2021

Clinical • Enrollment change • Trial completion date • Trial primary completion date • BRCA • HER-2